Insights into next developments in advanced gastric cancer

J 2016

Insights into next developments in advanced gastric cancer

OBERMANNOVÁ, Radka a Florian LORDICK

Základní údaje

Originální název

Insights into next developments in advanced gastric cancer

Autoři

OBERMANNOVÁ, Radka (203 Česká republika, garant, domácí) a Florian LORDICK (276 Německo)

Vydání

Current Opinion in Oncology, Philadelphia, Lippincott Williams and Wilkins, 2016, 1040-8746

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.414

Kód RIV

RIV/00216224:14110/16:00094109

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1097/CCO.0000000000000289

UT WoS

000377925900017

Klíčová slova anglicky

chemotherapy; gastric cancer; genetics; immune therapy; targeted therapy

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 4. 2017 14:57, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Purpose of review The purpose of the review is to delineate novel approaches for biology-based treatment in advanced gastric cancer. We reviewed the latest translational and clinical research articles and congress presentations. Recent findings A new molecular classification of gastric cancer based on histology, genetic and proteomic alterations has evolved. It provides a roadmap for development of new drugs and combinations and for patient stratification. Anti-HER2 treatment, which is an effective strategy in metastatic gastric cancer, is now also being studied in the perioperative setting. However, resistance mechanisms in advanced disease are poorly understood and optimal patient selection remains challenging. Targeting angiogenesis is an emerging concept in the management of advanced gastric cancer, and ramucirumab has prolonged survival in the second line either as a monotherapy or in combination with paclitaxel. Biomarkers for selecting patients who benefit from ramucirumab are still lacking. Immune checkpoint blockade and inhibition of cancer stemness targets are other emerging directions for the medical treatment of gastric cancer. Large-scale international studies are ongoing. Summary Promising biology-based treatment strategies are evolving. But tumor heterogeneity which is an inherent feature of gastric cancer challenges the development of molecularly targeted and personalized treatment strategies.

Citovat

OBERMANNOVÁ, Radka a Florian LORDICK. Insights into next developments in advanced gastric cancer. Current Opinion in Oncology. Philadelphia: Lippincott Williams and Wilkins, 2016, roč. 28, č. 4, s. 367-375. ISSN 1040-8746. Dostupné z: https://dx.doi.org/10.1097/CCO.0000000000000289.

@article{1378073,
   author = {Obermannová, Radka and Lordick, Florian},
   article_location = {Philadelphia},
   article_number = {4},
   doi = {http://dx.doi.org/10.1097/CCO.0000000000000289},
   keywords = {chemotherapy; gastric cancer; genetics; immune therapy; targeted therapy},
   language = {eng},
   issn = {1040-8746},
   journal = {Current Opinion in Oncology},
   title = {Insights into next developments in advanced gastric cancer},
   volume = {28},
   year = {2016}
}

TY  - JOUR
ID  - 1378073
AU  - Obermannová, Radka - Lordick, Florian
PY  - 2016
TI  - Insights into next developments in advanced gastric cancer
JF  - Current Opinion in Oncology
VL  - 28
IS  - 4
SP  - 367-375
EP  - 367-375
PB  - Lippincott Williams and Wilkins
SN  - 10408746
KW  - chemotherapy
KW  - gastric cancer
KW  - genetics
KW  - immune therapy
KW  - targeted therapy
N2  - Purpose of review The purpose of the review is to delineate novel approaches for biology-based treatment in advanced gastric cancer. We reviewed the latest translational and clinical research articles and congress presentations. Recent findings A new molecular classification of gastric cancer based on histology, genetic and proteomic alterations has evolved. It provides a roadmap for development of new drugs and combinations and for patient stratification. Anti-HER2 treatment, which is an effective strategy in metastatic gastric cancer, is now also being studied in the perioperative setting. However, resistance mechanisms in advanced disease are poorly understood and optimal patient selection remains challenging. Targeting angiogenesis is an emerging concept in the management of advanced gastric cancer, and ramucirumab has prolonged survival in the second line either as a monotherapy or in combination with paclitaxel. Biomarkers for selecting patients who benefit from ramucirumab are still lacking. Immune checkpoint blockade and inhibition of cancer stemness targets are other emerging directions for the medical treatment of gastric cancer. Large-scale international studies are ongoing. Summary Promising biology-based treatment strategies are evolving. But tumor heterogeneity which is an inherent feature of gastric cancer challenges the development of molecularly targeted and personalized treatment strategies.
ER  -

OBERMANNOVÁ, Radka a Florian LORDICK. Insights into next developments in advanced gastric cancer. \textit{Current Opinion in Oncology}. Philadelphia: Lippincott Williams and Wilkins, 2016, roč.~28, č.~4, s.~367-375. ISSN~1040-8746. Dostupné z: https://dx.doi.org/10.1097/CCO.0000000000000289.

Podrobný výpis o publikaci